NCT06957821View on ClinicalTrials.gov

Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

July 30, 2027

Study Completion Date

December 31, 2027

Conditions
Carotid Artery DiseasesPeripheral Arterial Disease
Interventions
DRUG

Pegulicianine

Pegulicianine (LUMISIGHT) Inflammatory activity

OTHER

Placebo

Control group for the study

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Massachusetts General Hospital

OTHER